Earnings Feed
Start Free
KYTHERA BIOPHARMACEUTICALS INC·4

Oct 2, 2:17 PM ET

KYTHERA BIOPHARMACEUTICALS INC 4

4 · KYTHERA BIOPHARMACEUTICALS INC · Filed Oct 2, 2015

Insider Transaction Report

Form 4
Period: 2015-10-01
KYTHERA BIOPHARMACEUTICALS INCKYTH
FENTON DENNIS M
Director
Transactions
  • Disposition to Issuer

    Common Stock

    2015-10-01−3,348→ 0 total(indirect: See Footnote)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−5,672→ 0 total
    Exercise: $5.29Exp: 2017-09-17→ Common Stock (5,672 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−8,400→ 0 total
    Exercise: $33.26Exp: 2024-06-05→ Common Stock (8,400 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−5,672→ 0 total
    Exercise: $5.90Exp: 2021-09-15→ Common Stock (5,672 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−5,672→ 0 total
    Exercise: $7.80Exp: 2021-11-02→ Common Stock (5,672 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−5,672→ 0 total
    Exercise: $11.69Exp: 2022-08-06→ Common Stock (5,672 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−5,672→ 0 total
    Exercise: $16.00Exp: 2022-10-10→ Common Stock (5,672 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−18,908→ 0 total
    Exercise: $0.76Exp: 2016-09-26→ Common Stock (18,908 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−6,618→ 0 total
    Exercise: $21.65Exp: 2023-06-04→ Common Stock (6,618 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2015-10-01−11,591→ 0 total
    Exercise: $53.26Exp: 2025-06-02→ Common Stock (11,591 underlying)
Footnotes (4)
  • [F1]Includes 1,476 shares previously held by the Reporting Person directly.
  • [F2]Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest.
  • [F3]Shares held by The Fenton Family Trust, dated January 23, 1991, Dennis M. Fenton and Linda M. Fenton, Trustees.
  • [F4]Pursuant to the Merger Agreement, each option to purchase common stock was canceled and paid in cash assuming a stock price of $75.00.

Documents

1 file
  • 4
    a4.xmlPrimary

    4